Copyright Reports & Markets. All rights reserved.

Global Targeted Drug VEGF Inhibitors for NSCLC Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Bevacizumab
      • 1.4.3 Other
    • 1.5 Market by Application
      • 1.5.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Share by Application (2014-2025)
      • 1.5.2 Squamous Cell Carcinoma of NSCLC
      • 1.5.3 Adenocarcinoma of NSCLC
      • 1.5.4 Large Cell Carcinoma of NSCLC
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size
    • 2.2 Targeted Drug VEGF Inhibitors for NSCLC Growth Trends by Regions
      • 2.2.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size by Regions (2014-2025)
      • 2.2.2 Targeted Drug VEGF Inhibitors for NSCLC Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Targeted Drug VEGF Inhibitors for NSCLC Market Size by by Players
      • 3.1.1 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue by by Players (2014-2019)
      • 3.1.2 Global Targeted Drug VEGF Inhibitors for NSCLC Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Targeted Drug VEGF Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
    • 3.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players Head office and Area Served
    • 3.3 Key Players Targeted Drug VEGF Inhibitors for NSCLC Product/Solution/Service
    • 3.4 Date of Enter into Targeted Drug VEGF Inhibitors for NSCLC Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type (2014-2019)
    • 4.2 Global Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Targeted Drug VEGF Inhibitors for NSCLC Market Size (2014-2019)
    • 5.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in United States
    • 5.3 United States Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
    • 5.4 United States Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application

    6 Europe

    • 6.1 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size (2014-2019)
    • 6.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Europe
    • 6.3 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
    • 6.4 Europe Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application

    7 China

    • 7.1 China Targeted Drug VEGF Inhibitors for NSCLC Market Size (2014-2019)
    • 7.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in China
    • 7.3 China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
    • 7.4 China Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application

    8 Japan

    • 8.1 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size (2014-2019)
    • 8.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Japan
    • 8.3 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
    • 8.4 Japan Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size (2014-2019)
    • 9.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Southeast Asia
    • 9.3 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
    • 9.4 Southeast Asia Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application

    10 India

    • 10.1 India Targeted Drug VEGF Inhibitors for NSCLC Market Size (2014-2019)
    • 10.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in India
    • 10.3 India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
    • 10.4 India Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size (2014-2019)
    • 11.2 Targeted Drug VEGF Inhibitors for NSCLC Key Players in Central & South America
    • 11.3 Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Type
    • 11.4 Central & South America Targeted Drug VEGF Inhibitors for NSCLC Market Size by Application

    12 International Players Profiles

    • 12.1 Roche
      • 12.1.1 Roche Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.1.4 Roche Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.1.5 Roche Recent Development
    • 12.2 Pfizer
      • 12.2.1 Pfizer Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.2.4 Pfizer Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.2.5 Pfizer Recent Development
    • 12.3 Allergan
      • 12.3.1 Allergan Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.3.4 Allergan Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.3.5 Allergan Recent Development
    • 12.4 Amgen
      • 12.4.1 Amgen Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.4.4 Amgen Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.4.5 Amgen Recent Development
    • 12.5 Biocon
      • 12.5.1 Biocon Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.5.4 Biocon Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.5.5 Biocon Recent Development
    • 12.6 Reliance Lifesciences
      • 12.6.1 Reliance Lifesciences Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.6.4 Reliance Lifesciences Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.6.5 Reliance Lifesciences Recent Development
    • 12.7 Beaconpharma
      • 12.7.1 Beaconpharma Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.7.4 Beaconpharma Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.7.5 Beaconpharma Recent Development
    • 12.8 Celgene Corporation
      • 12.8.1 Celgene Corporation Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.8.4 Celgene Corporation Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.8.5 Celgene Corporation Recent Development
    • 12.9 Fujifilm Kyowa Kirin Biologics
      • 12.9.1 Fujifilm Kyowa Kirin Biologics Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.9.4 Fujifilm Kyowa Kirin Biologics Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.9.5 Fujifilm Kyowa Kirin Biologics Recent Development
    • 12.10 Hetero Drugs
      • 12.10.1 Hetero Drugs Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Targeted Drug VEGF Inhibitors for NSCLC Introduction
      • 12.10.4 Hetero Drugs Revenue in Targeted Drug VEGF Inhibitors for NSCLC Business (2014-2019)
      • 12.10.5 Hetero Drugs Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      In 2018, the global Targeted Drug VEGF Inhibitors for NSCLC market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Targeted Drug VEGF Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drug VEGF Inhibitors for NSCLC development in United States, Europe and China.

      The key players covered in this study
      Roche
      Pfizer
      Allergan
      Amgen
      Biocon
      Reliance Lifesciences
      Beaconpharma
      Celgene Corporation
      Fujifilm Kyowa Kirin Biologics
      Hetero Drugs

      Market segment by Type, the product can be split into
      Bevacizumab
      Other

      Market segment by Application, split into
      Squamous Cell Carcinoma of NSCLC
      Adenocarcinoma of NSCLC
      Large Cell Carcinoma of NSCLC

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Targeted Drug VEGF Inhibitors for NSCLC status, future forecast, growth opportunity, key market and key players.
      To present the Targeted Drug VEGF Inhibitors for NSCLC development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Targeted Drug VEGF Inhibitors for NSCLC are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now